CN103251518B - use of heparin for skin whitening - Google Patents
use of heparin for skin whitening Download PDFInfo
- Publication number
- CN103251518B CN103251518B CN201210090489.7A CN201210090489A CN103251518B CN 103251518 B CN103251518 B CN 103251518B CN 201210090489 A CN201210090489 A CN 201210090489A CN 103251518 B CN103251518 B CN 103251518B
- Authority
- CN
- China
- Prior art keywords
- skin
- heparin
- present
- moisture
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960002897 heparin Drugs 0.000 title claims abstract description 61
- 229920000669 heparin Polymers 0.000 title claims abstract description 61
- 230000002087 whitening effect Effects 0.000 title abstract description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 5
- 210000002808 connective tissue Anatomy 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 230000009759 skin aging Effects 0.000 abstract description 14
- 230000003020 moisturizing effect Effects 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 107
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- -1 poly-alkaryl siloxanes Chemical class 0.000 description 21
- 239000000194 fatty acid Substances 0.000 description 18
- 238000007689 inspection Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 229920002545 silicone oil Polymers 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010971 suitability test Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003721 exogen phase Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XTQUSEDRZLDHRC-UHFFFAOYSA-N 3-octadecanoyloxybutyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCCCCCCCCCCCC XTQUSEDRZLDHRC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000256846 Apis cerana Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000931888 Pyxis Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005376 alkyl siloxane group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002086 anti-sebum Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- NZIKRHKSEITLPS-UHFFFAOYSA-N butane-1,3-diol;octadecanoic acid Chemical compound CC(O)CCO.CCCCCCCCCCCCCCCCCC(O)=O NZIKRHKSEITLPS-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
The invention relates to a novel application of heparin in skin moisturizing, whitening and skin aging prevention, which is used for moisturizing and whitening skin and preventing skin aging. The present invention also relates to a pharmaceutical composition for moisturizing skin, whitening skin and preventing skin aging, which comprises heparin.
Description
Technical field
The present invention relates to a kind of purposes of heparin; In specific words, the present invention about heparin in skin moisture-keeping, whitening and the purposes preventing skin aging.
Background technology
Heparin (heparin) is that a kind of straight chain formula anion glucamine gathers candy, and extensively exists in animal connective tissue's mastocyte, therefore can therefrom extract further and be used.Current research finds that heparin has many biological activitys, fibroblast proliferation such as suppressing fibrin deposition in tissue relevant with protease with suppression etc.Heparin, mainly as a kind of anticoagulant, has blood coagulation resisting function in vivo and in vitro.Be mainly used in prevention and therapy thromboembolic disorders clinically, and use as anticoagulant or antiinflammatory agents; Such as, myocardial infarction, operation on vessels of heart, cardia catheterization, external loop, hemodialysis etc.
Find that heparin still can be applicable in skin cleaner at present, such as CN1475202A discloses a kind of skin-cleaning cosmetics containing heparin, in page 4 the 8 to 9 row, it points out that heparin mainly contains anticoagulation, antithrombotic, Adjust-blood lipid and by biological activitys such as low blood viscositys, and point out that this skin-cleaning cosmetics is through further and improve skin microcirculation, reduce blood viscosity, promote blood microcirculation and skin metabolism, to reach skin-active cosmetic result, therefore it is main or be applied to further on skin for anticoagulant function by heparin.
Therefore, many-sided application of heparin to be developed is still had at present.In addition, in cosmetics industry for can local coating to skin and aging resistance is provided, demand that the product of moisturizing and white-skinned face function still has development.
Summary of the invention
Before making the present invention, any report or prior art are not pointed out or infer that heparin can be used for the purposes that moisturizing, whitening and aging resistance etc. improve skin.
Term " skin " includes but not limited to face, neck, breast, the back of the body, arm, oxter, the skin on hands and head capsule.
Term " skin moisture-keeping " refers to can increase moisture content of skin, maintain the normal moisture loss of skin and/or not cutaneous fat secretion amount.
Term " skin-whitening " refers to increase the melanin of skin or speckle amount, maybe can increase the lightness of skin.
Term " prevents skin aging " refers to reduce the enlarged pores number of skin, the roughness reducing skin, the wrinkle rate reducing skin or increase skin elasticity.In detail, term " prevents from " representing prevention or stoping symptom to produce, or improves or reply the symptom produced; Term " skin aging " comprises following various aging sign and includes but not limited to skin fragility; The forfeiture of elastin laminin; Oestrogen balance disappearance in skin; Atrophoderma; The appearance of lines or wrinkle or the degree of depth, comprise fine lines; Dyschromasia, comprises black eye; Cutis laxa; Skin fatigue or pressure, such as, skin caused by ambient pressure such as pollution or variations in temperature is given prominence to; Dry skin; Skin scales off; Cell senescence; The forfeiture of skin tension, elasticity or gloss; The forfeiture of skin firmness; Rough bark quality; Skin elasticity or elastic forfeiture.
On the one hand, the object of this invention is to provide a kind of heparin or its purposes that is pharmaceutically acceptable or cosmetically acceptable salt, it is for promoting skin moisture-keeping, skin-whitening and preventing skin aging.
According to the present invention, any heparin or its pharmaceutically acceptable or cosmetically acceptable salt purposes of all can be used for skin moisture-keeping as described in the present invention, skin-whitening and preventing skin aging.According to one of the present invention specific embodiment, heparin pharmaceutically acceptable or cosmetically acceptable salt can be sodium salt, potassium salt, lithium salts, ammonium salt, phosphate, sulfate and hydrochlorate.According to one of the present invention specific embodiment, heparin can be the position of animal (as pig, cattle) containing connective tissue as the heparin extract of intestinal mucosa, liver and lungs, chemosynthesis heparin or genetic engineering synthesis heparin.Preferably, heparin is the heparin extract of intestinal mucosa or lungs.Above-mentioned heparin extract, chemosynthesis heparin or genetic engineering synthesis heparin can prepare (Guo Xifeng, 2008, meat industry by method known in skill; Wang Zhengteng, 1988, science agricultural).
According to the present invention, heparin or its pharmaceutically acceptable or cosmetically acceptable salt can be used for skin moisture-keeping.Skin is the outermost organ of human body, avoids being subject to except the injury of extraneous various stimulation except protecting us, also bears the vital task preventing moisture loss simultaneously.Substantially, if the humidity in air is lower than 30 percent, moisture will easily be scattered and disappeared by skin.Transdermal outer oils and fats, middle level horny layer and internal layer water absorption factor, prevent the loss of moisture.Outer oils and fats, by smegma, forms thin film at skin surface, prevents evapotranspiring of moisture.Horny layer is the outermost part of epidermis, does not have nuclear dead cell to form primarily of 15 to 20 layers.When these cell detachments, the cell that beneath face is positioned at basal layer can be brought to, and forms new horny layer.Containing keratin (keratin) in cuticular cell.It helps minimizing moisture loss, even can absorb moisture content, makes skin keep moistening.The cell membrane of keratinocyte in horny layer, the combined water of cellular content and intercellular matrix, determines the flexibility of skin.Internal layer water absorption factor is the hyaluronic acid in the natural water absorption factor (such as amino acid, carbamide, PCA etc.) of skin inner layer and skin corium, can absorb moisture, keep skin wet.
According to the present invention, heparin or its pharmaceutically acceptable or cosmetically acceptable salt can be used for skin-whitening.Melanin is a kind of protein being present in everyone skin base layer.Ultraviolet irradiation can make melanin change, and generates a kind of material protecting skin, then melanin moving layer by layer again via cellular metabolism, has arrived skin epidermal area, defines our present seen mottle and the skin problem such as the colour of skin is irregular.Whitening reach can by minimizing melanin formed, stimulated by preventing melanocyte and suppresses Tyrosinase to achieve the goal, reduce melanin be released into epidermis cell, acceleration melanin leave each layer of epidermis to prevent melanocyte from being stimulated, activate and manufacture melanin.
According to the present invention, heparin or its pharmaceutically acceptable or cosmetically acceptable salt can be used for preventing skin aging.The reason of skin aging includes the factor of endogenous and exogen.The endogenous aging biologic clocks being gene and being just doomed, along with the increase at age, the vital stage of cell shortens, and split speed is also slack-off, therefore thinning of skin, lipoatrophy, define the phenomenons such as cheek depression is lax.The injury that the catabiosis that exogen factor causes includes pollution in external environment, harmful substance causes skin, such as ultraviolet.Skin aging sign is that skin is thinner, dry and lack flexibility, and produces yellow cord, and wrinkle intensification etc.
According to the present invention, the reaction of heparin nonirritant is confirmed through human body skin result of the test, represent and be applicable to human body skin, and can moisture content of skin be promoted, increase skin elasticity, improve wrinkle, reduce skin enlarged pores number, there is skin moisture-keeping, smooth microgroove, compact skin and the aging effect of delaying skin.
On the other hand, the invention provides a kind of skin moisture-keeping, skin-whitening and prevent the compositions of skin aging, it comprises heparin or its pharmaceutically acceptable or cosmetically acceptable salt, and one or more supporting agent.
According to the present invention, this supporting agent can be aqueous solution or emulsion.When having moisture, its amount can be 5 to 99 % by weight, and preferably 40 to 90 % by weight, and the best is between 50 and 85 % by weight.
According to the present invention, this supporting agent preferably be have this supporting agent weight at least 50 % by weight water.Present composition preferably is oil-in-water emulsions, to improve transdermal delivery.In the better O/w emulsion of the present invention, water occupies at least 50 % by weight of emulsion of the present invention, and the best is 50 to 90 % by weight of compositions.
In addition to water, quite volatile solvent also can in the compositions of the present invention with being supporting agent.The best is monohydroxy C1-C3 alkanol.They comprise ethanol, methanol and isopropyl alcohol.The content of monohydroxy alkanols can be 1 to 80 % by weight, and preferably 10 to 60 % by weight, and the best is between 15 and 50 % by weight.
Lubricant also can with being acceptable supporting agent of making up, and they can be the form of silicone oil and synthesizing ester.The amount of lubricant can be 0.1 to 50 % by weight, between preferably 1 and 20 % by weight.
Silicone oil can be divided into volatility and non-volatile two kinds." volatility " one word refer to the material under Zhou Wen with measurable vapour pressure.Volatile silicone oil preferably is selected from containing 3 to 9, the ring-type of preferably's 4 to 5 silicon atoms or linear polydimethysiloxane person.Linear volatile silicone species has at 25 DEG C that annular material typically has the viscosity lower than about 10 lis of histories lower than the viscosity of about 5 lis of histories (centistokes) usually.The nonvolatile silicone oil that can be used as lubricant material comprises poly-alkylsiloxane, poly-alkaryl siloxanes and polyether siloxane copolymer.
Ester lubricant is: 1. alkenyl esters or the Arrcostab with the fatty acid of 10 to 20 carbon atoms, such as, include but not limited to, neopentanoic acid different Semen arachidis hypogaeae base ester, the different nonyl ester of different n-nonanoic acid, myristic acid oil base ester, stearic acid oil base ester, and oleic acid oil base ester, 2. the fatty acid ester of ether-ester class such as B oxidation fat alcohol, 3. polyhydroxy-alcohol esters, such as, include but not limited to, ethylene glycol-fatty acid ester and two-fatty acid ester, diethylene glycol one-and two-fatty acid ester, Polyethylene Glycol (200-6000) one-and two-fatty acid ester, propylene glycol one-and two-fatty acid ester, polypropylene glycol 2000-oleate, polypropylene glycol 2000-stearate, ethoxyquin propylene glycol-stearate, glyceryl one-and two-fatty acid ester, polyglycereol many fatty acid ester, ethoxy-lated glycerol base-stearate, 1, 3-butanediol monostearate, 1, 3-butanediol distearate, polyoxyethylated polyols fatty acid ester, sorbitan fatty acid ester, and Polyoxyethylene sorbitan fatty acid ester is all gratifying polyhydroxy-alcohol esters, 4. wax ester class, such as, Apis cerana Fabricius, spermaceti, myristic acid myristyl ester, stearyl stearate, with behenic acid Semen arachidis hypogaeae base ester, 5. sterol ester, such as, cholesterol fatty acid ester.
The wetting agent (humectants) of polyhydroxy-alcohol type also can be used for can accepting supporting agent as cosmetic in the present composition.Wetting agent contributes to the utility and the improvement skin texture that increase lubricant.Typical polyhydroxy-alcohol comprises glycerol, gathers and stretches alkane glycol, and better person stretches alkane glycol and its derivant, comprise propylene glycol, dipropylene glycol, polypropylene glycol, Polyethylene Glycol and its derivant, Sorbitol, hydroxypropyl sorbitol, hexanediol, 1,3 butylene glycol, 1,2,6-hexanetriol, ethoxy-lated glycerol, the mixture of glycerol propoxylate and they.For optimum, wetting agent preferably is propylene glycol or glass alduronic acid sodium.The amount of wetting agent can be 0.5 to 40% of composition weight, preferably 1 to 20%.
Also thickening agent can be used can to accept the part of supporting agent as making up contained by the present composition.Typical case's thickening agent comprises cross linked acrylic (as Carbopol982), through the acrylate (as Carbopoll382) of hydrophobic upgrading, and cellulose derivative and natural gum.Available fiber derivative comprises sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, ethyl cellulose and hydroxy methocel.Be applicable to the present invention's natural gum used and comprise the magnificent locust beam gum in bitter pass (guargum), xanthan gum, antler glue, the combination of pectin and they's resin.The amount of thickening agent can be 0.0001 to 8 % by weight.Be preferably 0.001 to 1 % by weight, the best 0.01 to 0.5 % by weight.Integrally, water, solvent, silicone, esters, fatty acid, it is 1 to 99.9 % by weight that wetting agent and/or thickening agent can form its amount, and the cosmetic of preferably 80 to 99 % by weight can accept supporting agent.
In addition can containing oil or grease, add that emulsifying agent is to make water-in-oil emulsion or O/w emulsion, major part is decided by the average hydrophilicity-hydrophobic balance (HLB) of emulsifying agent used.
Also interfacial agent can be contained in make-up composition of the present invention.The total concentration of interfacial agent is 0.1 to 50% of composition weight, preferably 1 to 30%, the best 1 to 5%.Interfacial agent can be selected from anion, nonionic, among the combination that cation and amphiprotic activity thing are formed.Special preferably non-ionic surfactant is C
10-C
20fatty alcohol or sour hydrophobic mass (hydrophobe) and 2 to 100 moles of ethylene oxide or expoxy propane every mole hydrophobic mass condensation gained person; C
2-C
10alkyl phenol and 2 to 20 mol of alkylene oxide class condensation gained persons; One-and two-fatty acid ester of ethylene glycol; Glycerol-fatty acid ester; Sorbitan one-and two-C
8-C
20fatty acid ester; Block copolymer (ethylene oxide/propylene oxide); And Polyoxyethylene sorbitan ether; And the combination of they.Alkyl poly glucoside and carbohydrate fatty acid amide (as methyl gluconamides) are also all suitable non-ionic surfactants.
Preferably teepol comprises soap class, alkyl ether sulphate salts and sulphonic acid ester salt, alkyl sulfate salt and sulphonic acid ester salt, alkylbenzenesulfonate, alkyl and dialkyl group sulfonic group succinic acid-ester salt, C
8-C
20acyl group ethylenehydrinsulfonic acid ester salt, acyl group glutamate, C
8-C
20the combination of alkyl ether phosphate and they.
There is other active component multiple can be included in make-up composition of the present invention.Active matter is through being defined as the skin benefit agent except the composition of lubricant and only improved composition institute tool physical characteristic.Such as, include but not limited to, anti-sebum composition, sunscreen, other whitening agents, wetting agent and age resister.
When using compositions of the present invention, by an amount, the compositions of 1 to 100 milliliter is applied to the exposure portion of skin, its desirable from appropriate containers or applicator and, when needing, with hands or finger or appropriate device by its spread on skin and/or wipe in skin.
The present composition can be any form, as can be formulated into toner (toner), gel, washing liquid, fluid cream, or emulsifiable paste.Said composition can be packaged in appropriate containers to coordinate the desired use of its viscosity and consumer.Such as, washing liquid or fluid cream can through be packaged in bottle or spin applicator or aerosol substrate-driving aerosol device or be equipped with the container of pump of applicable finger manipulation.When compositions is emulsifiable paste, it merely can be stored in indeformable bottle or can extrusion-type container, such as, in pipe or pyxis etc.Accordingly the present invention also propose a kind of be equipped with to make up as herein defined can accept the hermetic container of compositions.The present composition also can via micro-coating technology, and such as micro-fat body (Liposome) or microcapsule (Microcapsule), to reach preservation or the laser propagation effect of expection.In addition, the present composition also can wrap in capsule.
Following examples should not be considered as exceedingly limiting the present invention.Persond having ordinary knowledge in the technical field of the present invention can modify to embodiment discussed in this article when not deviating from spirit of the present invention or category and change, and still belongs to scope of the present invention.
Accompanying drawing explanation
Fig. 1: the essence containing heparin is applied in face's skin quality of 6 weeks (skin moisture-keeping).
Fig. 2: the essence containing heparin is applied in face's skin quality of 6 weeks (skin-whitening).
Fig. 3: be applied in face's skin quality of 6 weeks (preventing skin aging) containing heparin essence lotion.
Fig. 4: the essence containing heparin is applied in the hand lightness of 6 weeks.
Fig. 5: containing the essence of heparin to the moisture retention of hand skin.
Detailed description of the invention
materials and methods
Instrument
The instrument below used is the instrument of Noninvasive:
(1) skin moisture-keeping analyzer (DermaUnitSSC3)
The water content of keratodermatitis, skin oil and fat secretory volume can be measured.
(2) percutaneous moisture loss analyzer (
tM210)
The water quantities of scattering and disappearing through epidermis can be measured.
(3) skin determination of viscoelasticity instrument (
mPA580Courage+KhazakaelectronicGmbH, Germany)
The coefficient of elasticity of skin, transepidermal water windage, skin oil and fat amount can be measured.
(4) computer image automatic analyzer (
canfieldScientificInc., USA)
The speckle number of skin, thick pore number, wrinkle number can be measured.
(5) melanin analyzer (
mX18, Germany)
Dermal melanin amount can be measured.
(6) skin analysis instrument (NF333NipponDenshoku, Japan)
The lightness of skin can be measured
(7) multi-functional skin quality analyser (MultipleAdaptorSystem, AramoTS, Aram)
The moisturizing of skin, speckle, roughness, elasticity, wrinkle depth can be measured.
the preparation of heparin essence of the present invention
Embodiment-containing the essence of heparin
Comparative example-do not prepare containing the essence of heparin
moisturizing, whitening and aging resistance tuerculoderma
Test method
1. the Skin Irritation Test of cosmetics
Each examines product, and selecting 20 women, 30 to 60 years old ages, is testee without skin allergy and skin disease patient, and on pretreatment, leading allergy test reaction (smearing inspection product in flexion of upper limb side 48 hours), determines that testee is without anaphylaxis person.
Use Finnchamber paster, get the capsule that appropriate inspection product are placed in paster, after making inspection product and skin fully contact 48 hours, take off paster, have a rest after cleaning skin, and after 1,3,24 hour, observe the red and swollen situation of skin according to skin irritation grade form, judge whether inspection product have zest.
2. the skin employment and suitability test (E & ST) of cosmetics
Each examines product, and selecting 20 women, 30 to 60 years old ages, is testee without skin disease patient.
Get appropriate inspection product, be applied on the skin of flexion of upper limb side 5x5cm, every twice-daily, continuous 30 days, every day observe whether have rubescent or itch wait discomfort reaction.If find that there is the sensation of any discomfort, then stopping immediately, and record the dermoreaction after its use inspection product, there is the percentage rate of skin sensitivity or discomfort in statistics after using inspection product.Judge whether being applicable on skin of inspection product.
3. the human body skin efficiency assessment of cosmetics
Each examines product, and select 20 women, 30 to 60 years old ages were testee without skin allergy and skin disease patient, and on pretreatment, leading allergy test reaction, determines that testee is without anaphylaxis person.
Sooner or later after washing one's face every day, about get inspection product 0.5mL (or 0.5g) gently to smear in face, continuous 6 weeks, in the 0th, 1,2,3,4,5,6 week time, testee carries out the detection analysis of skin via the instrument of every Noninvasive, after the every data statistical analysis of gained, to assess the effect that inspection product improve skin quality.
4. the moisturizing assessment of cosmetics:
Each examines product, selects 20 women, 30 to 60 years old ages, without irritated medical history person, tests first 24 hours tested skin parts and does not smear any skin care products or medicine.
During experiment, testee cleans tested inner forearm skin with water, wipe dry after cleaning, under temperature 20 ± 1 DEG C, humidity 45%-50%RH, have a rest 30 minutes, and labelling 4 test positions, each test position is diameter 3 centimeters of regions, and right-hand man is respectively L-1 to L-4, R-1 to R-4 by inside wrist to elbow.Get appropriate inspection product, be applied on the skin of institute's labelling on testee arm at random, as blank group, smear evenly latter every 30 minutes using pure water (or solvent of dilution inspection product), continuous 3 hours, measure the change of keratodermatitis water content with skin analyzer.Every 60 minutes, to evapotranspire analyzer with moisture of skin, measure the change of moisture via epidermis windage.
Result of the test
1. examine the Skin Irritation Test of product
Get respectively containing heparin extract (300ug/mL) essence, be not placed in the capsule of Finnchamber paster respectively containing the essence of heparin extract, after fully contacting 48 hours with skin, take off paster cleaning skin, have a rest after 1 hour, 20 testee skin is all without any red, swollen or uncomfortable phenomenon such as to itch, and in whole process, testee, also without any discomfort sensation, represents that the essence containing heparin extract reacts the equal nonirritant of skin.
2. examine the skin employment and suitability test (E & ST) of product
Get containing heparin (300ug/mL) essence, not containing the essence of heparin, each inspection product is applied in the flexion of upper limb side of 20 testees respectively, after 6 weeks, all without occurring the sensation of any discomfort or bad dermoreaction.
3. examine the human body skin efficiency assessment of product
Experimental result is as shown in table 1, table 2 and Fig. 1 to 4:
By above-described embodiment, provable the present invention is applicable to skin, and further for skin moisture-keeping, skin-whitening and prevent skin aging from all having obvious effect.
In Skin Irritation Test, containing the essence of heparin extract (300ug/mL), to the equal nonirritant reaction of the skin of 20 testees; In skin employment and suitability test (E & ST), containing the essence of heparin extract (300ug/mL), use through 20 people and be applied in flexion of upper limb side after 6 weeks, all without occurring the sensation of any discomfort or bad dermoreaction, representing and being applicable to skin.
In human body skin efficiency assessment, containing the essence of heparin extract (300ug/mL) human body skin efficiency assessment result for facial skin moisture retention (cleaning after without inspection product time), slightly can increase moisture content of skin, maintain the normal moisture loss of skin, and not cutaneous fat secretion amount; For facial skin whitening (time after cleaning without inspection product), heparin extract can not increase melanin or the speckle amount of skin, and slightly can increase the lightness of skin; For face prevent aging (cleaning after without inspection product time), heparin extract can slightly reduce skin enlarged pores number, can reduce skin roughness, can reduce skin wrinkle rate and can skin elasticity be increased; For hand skin whitening, heparin extract slightly can increase the lightness of skin; For hand skin moisturizing (when scribbling inspection product), heparin extract has obvious moistening effect for hand skin.
Claims (5)
1. a heparin or its pharmaceutically acceptable or cosmetically acceptable salt promote the purposes of skin-whitening medicine as sole active agent preparation.
2. purposes as claimed in claim 1, wherein this heparin pharmaceutically acceptable or cosmetically acceptable salt be sodium salt, lithium salts, ammonium salt, phosphate, sulfate and hydrochlorate.
3. purposes as claimed in claim 1, wherein this heparin is that animal contains the heparin extract at the position of connective tissue, chemosynthesis heparin or genetic engineering synthesis heparin.
4. purposes as claimed in claim 3, wherein this heparin is the heparin extract that animal contains the position of connective tissue.
5. purposes as claimed in claim 4, wherein this animal is intestinal mucosa or lungs containing the position of connective tissue.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW101105480A TW201334803A (en) | 2012-02-20 | 2012-02-20 | Novel use of heparin in moisturizing and whitening skin and preventing skin aging |
| TW101105480 | 2012-02-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103251518A CN103251518A (en) | 2013-08-21 |
| CN103251518B true CN103251518B (en) | 2016-01-20 |
Family
ID=48955963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210090489.7A Expired - Fee Related CN103251518B (en) | 2012-02-20 | 2012-03-30 | use of heparin for skin whitening |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103251518B (en) |
| TW (1) | TW201334803A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953757A (en) * | 2010-09-21 | 2011-01-26 | 广州舒泰生物技术有限公司 | Freeze-dried gel cosmetic and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3687277B2 (en) * | 1997-06-10 | 2005-08-24 | サンスター株式会社 | Whitening cosmetics |
-
2012
- 2012-02-20 TW TW101105480A patent/TW201334803A/en unknown
- 2012-03-30 CN CN201210090489.7A patent/CN103251518B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953757A (en) * | 2010-09-21 | 2011-01-26 | 广州舒泰生物技术有限公司 | Freeze-dried gel cosmetic and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201334803A (en) | 2013-09-01 |
| CN103251518A (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6843863B2 (en) | Compositions containing at least two fatty acid esters of (poly) glycerol, and their use in cosmetics | |
| US10022396B2 (en) | Compositions and methods for treating conditions of compromised skin barrier function | |
| JP2021168948A (en) | Composition and method for application to skin | |
| ES2381359T3 (en) | Compositions containing mixtures of tetrapeptides and tripeptides | |
| CN104010662B (en) | Make compositions and method that skin rejuvenates | |
| US8357360B2 (en) | Cosmetic compositions containing an aqueous dispersion of silicone elastomers and methods of use | |
| JP5686365B2 (en) | Collagen production promoter, photoaging inhibitor, moisturizing function improving agent and dermatological composition | |
| US20210393507A1 (en) | Extemporaneous cosmetic and/or dermatological preparations | |
| TW200803910A (en) | Glyceryl and glycol acid compounds | |
| JP2022511023A (en) | New cosmetic and dermatological uses of extracts of Cistus monsperiensis | |
| JP2013539792A (en) | Use of monoamine oxidase inhibitors to improve epithelial ecology | |
| JP2023547984A (en) | Tissue-derived matrix composition and method thereof | |
| JP5787246B2 (en) | Wound healing and pressure ulcer (bed sores) treatment, including keratinocyte migration / proliferation promoter | |
| US10780029B2 (en) | Triphasic cleansing composition | |
| CN103251518B (en) | use of heparin for skin whitening | |
| JP2020033346A (en) | Topical composition containing pichia anomala and n-acetylglucosamine | |
| JP2019202996A (en) | COSMETIC COMPOSITION COMPRISING γ-POLYGLUTAMIC ACID AS ACTIVE COMPONENT | |
| Leite-Silva et al. | The Influence of emollients on dermal and transdermal drug delivery | |
| Ainurofiq et al. | Characterization and application of moisturizer in skin treatment: A review: Moisturizer in Skin Treatment | |
| CN107049814A (en) | Suppress matrix metal egg from enzyme and the method and related cooperative compositions that reduce skin aging | |
| KR101526592B1 (en) | Anti-wrinkle composition | |
| Somwanshi et al. | Cosmetic Science | |
| JP2023174219A (en) | Composition including diisopropylamine dichloroacetate | |
| JP2024046365A (en) | Transglutaminase production promoter and its use | |
| Leite-Silva et al. | Yousuf Mohammed, Hamid R. Moghimi, and Michael S. Roberts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20200330 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |